Triple-negative breast cancer (TNBC) represents approximately 15–20% of all breast carcinomas and is defined by the absence of immunohistochemical expression of estrogen receptor (ER) and progesterone receptor (PR), as well as the lack of HER2 protein overexpression or HER2 gene amplification [1]. This evidence concerns the gene PGR and triple-negative breast carcinoma.